Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
79 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Alnylam Pharmaceuticals, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Alnylam Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Alnylam Pharmaceuticals, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Alnylam Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Alnylam Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Alnylam Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Alnylam Pharmaceuticals, Inc.'s pipeline products Reasons to buy - Evaluate Alnylam Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Alnylam Pharmaceuticals, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Alnylam Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Alnylam Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Alnylam Pharmaceuticals, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Alnylam Pharmaceuticals, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Alnylam Pharmaceuticals, Inc. Snapshot 6 Alnylam Pharmaceuticals, Inc. Overview 6 Key Information 6 Key Facts 6 Alnylam Pharmaceuticals, Inc. - Research and Development Overview 7 Key Therapeutic Areas 7 Alnylam Pharmaceuticals, Inc. - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Out-Licensed Products 12 Out-Licensed Products/Combination Treatment Modalities 13 Alnylam Pharmaceuticals, Inc. - Pipeline Products Glance 14 Alnylam Pharmaceuticals, Inc. - Late Stage Pipeline Products 14 Phase III Products/Combination Treatment Modalities 14 Alnylam Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 15 Phase II Products/Combination Treatment Modalities 15 Phase I Products/Combination Treatment Modalities 16 Alnylam Pharmaceuticals, Inc. - Early Stage Pipeline Products 17 Preclinical Products/Combination Treatment Modalities 17 Discovery Products/Combination Treatment Modalities 18 Alnylam Pharmaceuticals, Inc. - Drug Profiles 19 patisiran 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 ALN-TTRSC 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 asvasiran sodium 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 ALN-AT3 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 ALN-PCS02 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 ALN-PCSsc 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 ALN-TTR-01 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 ALN-VSP 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 ALN-AAT 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 ALN-ANG 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 ALN-APC 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 ALN-AS1 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 ALN-CC5 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 ALN-HPN 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 ALN-HTT 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 ALN-TMP 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Dendritic Cell Vaccine for Cancer and Viral Infections 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 LNP-dsP21-322-2'F 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 RNAi Therapeutics for Parkinson's Disease 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 SIRNA-034 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 MicroRNA for Orphan Diseases 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Alnylam Pharmaceuticals, Inc. - Pipeline Analysis 44 Alnylam Pharmaceuticals, Inc. - Pipeline Products by Target 44 Alnylam Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 46 Alnylam Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 47 Alnylam Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 48 Alnylam Pharmaceuticals, Inc. - Recent Pipeline Updates 49 Alnylam Pharmaceuticals, Inc. - Dormant Projects 71 Alnylam Pharmaceuticals, Inc. - Company Statement 72 Alnylam Pharmaceuticals, Inc. - Locations And Subsidiaries 77 Head Office 77 Other Locations & Subsidiaries 77 Appendix 78 Methodology 78 Coverage 78 Secondary Research 78 Primary Research 78 Expert Panel Validation 78 Contact Us 79 Disclaimer 79
List of Tables Alnylam Pharmaceuticals, Inc., Key Information 6 Alnylam Pharmaceuticals, Inc., Key Facts 6 Alnylam Pharmaceuticals, Inc. - Pipeline by Indication, 2014 8 Alnylam Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 10 Alnylam Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 11 Alnylam Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2014 12 Alnylam Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 13 Alnylam Pharmaceuticals, Inc. - Phase III, 2014 14 Alnylam Pharmaceuticals, Inc. - Phase II, 2014 15 Alnylam Pharmaceuticals, Inc. - Phase I, 2014 16 Alnylam Pharmaceuticals, Inc. - Preclinical, 2014 17 Alnylam Pharmaceuticals, Inc. - Discovery, 2014 18 Alnylam Pharmaceuticals, Inc. - Pipeline by Target, 2014 45 Alnylam Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 46 Alnylam Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 47 Alnylam Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 48 Alnylam Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 49 Alnylam Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 71 Alnylam Pharmaceuticals, Inc., Subsidiaries 77
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
